- Home
- ARMP vs STRO Comparison
ARMP vs STRO Comparison
Compare ARMP & STRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARMP
- STRO
- Stock Information
- Founded
- ARMP N/A
- STRO 2003
- Country
- ARMP United States
- STRO United States
- Employees
- ARMP N/A
- STRO N/A
- Industry
- ARMP Biotechnology: Biological Products (No Diagnostic Substances)
- STRO Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ARMP Health Care
- STRO Health Care
- Exchange
- ARMP Nasdaq
- STRO Nasdaq
- Market Cap
- ARMP 52.1M
- STRO 50.0M
- IPO Year
- ARMP N/A
- STRO 2018
- Fundamental
- Price
- ARMP $1.23
- STRO $0.52
- Analyst Decision
- ARMP Strong Buy
- STRO Buy
- Analyst Count
- ARMP 1
- STRO 7
- Target Price
- ARMP $7.00
- STRO $6.83
- AVG Volume (30 Days)
- ARMP 30.3K
- STRO 1.4M
- Earning Date
- ARMP 05-06-2025
- STRO 05-12-2025
- Dividend Yield
- ARMP N/A
- STRO N/A
- EPS Growth
- ARMP N/A
- STRO N/A
- EPS
- ARMP N/A
- STRO N/A
- Revenue
- ARMP $5,174,000.00
- STRO $62,043,000.00
- Revenue This Year
- ARMP $8.43
- STRO N/A
- Revenue Next Year
- ARMP N/A
- STRO $1.29
- P/E Ratio
- ARMP N/A
- STRO N/A
- Revenue Growth
- ARMP 14.24
- STRO N/A
- 52 Week Low
- ARMP $0.90
- STRO $0.54
- 52 Week High
- ARMP $3.45
- STRO $5.17
- Technical
- Relative Strength Index (RSI)
- ARMP 39.22
- STRO 29.82
- Support Level
- ARMP $1.11
- STRO $0.54
- Resistance Level
- ARMP $1.30
- STRO $0.78
- Average True Range (ATR)
- ARMP 0.14
- STRO 0.09
- MACD
- ARMP 0.01
- STRO 0.02
- Stochastic Oscillator
- ARMP 42.86
- STRO 0.00
About ARMP Armata Pharmaceuticals Inc.
Armata Pharmaceuticals Inc is a developer of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. The company is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. In addition, in collaboration with Merck, the company is developing proprietary synthetic phage candidates to target an undisclosed infectious disease agent.
About STRO Sutro Biopharma Inc.
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. The company also pipeline contains STRO-004, STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.